First quarter results 2018


First quarter 2018 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

We continue to execute on our business priorities and position the Company for a new period of growth which is expected to begin in the second half of 2018

Olivier Brandicourt

Chief Executive Officer



Clinical trials appendix

Press release – April 27, 2018: First-quarter 2018 Business EPS up 1.4% at CER

Q1 2018 income statements

Q1 2018 net sales by GBU, franchise, geographic region and product